This course has expired. View available courses.
Endocrinology, Oncology
Closing the Knowledge Gap: RAI-Refractory Differentiated Thyroid Cancer
Differentiated thyroid cancer (DTC) is the most common type of thyroid cancer. Of those patients diagnosed with DTC, approximately 5 to 15% may be RAI-Refractory. There is currently no consensus that defines RAI-refractory differentiated thyroid cancer (RAIR-DTC) or offers clinical scenarios that are an absolute indicator of the condition. To address this topic, this program […]
DURATION
30 mins
PROFESSION
Physician, Specialist
# OF CREDITS
0.5
ACCREDITATION
MOC - Section 3
EXPIRY DATE
2021-02-14
Differentiated thyroid cancer (DTC) is the most common type of thyroid cancer. Of those patients diagnosed with DTC, approximately 5 to 15% may be RAI-Refractory. There is currently no consensus that defines RAI-refractory differentiated thyroid cancer (RAIR-DTC) or offers clinical scenarios that are an absolute indicator of the condition. To address this topic, this program consists of short educational videos on Differentiated thyroid cancer and the treatment of RAI-Refractory patients. Dr. Stan VanUum and Dr. Dean Ruether will discuss common issues healthcare professionals, including endocrinologists and oncologists, may have concerning the challenges of identifying and treating RAIR-DTC patients.
Faculty
Dr. Andree Boucher, MD, FRCPC
Dr. Murali Rajamaran, MD, FRCPC
Dr. Stan VanUum, MD, PhD, FRCPC
Dr. Dean Ruether, MD, FRCPC
Learning objectives
Upon completion of this program, the participants will be able to:
- Identify differentiated thyroid cancer patients likely to be RAI-Refractory (RAIR-DTC)
- Initiate treatment with a tyrosine kinase inhibitor (TKI) in RAI-Refractory Differentiated Thyroid Cancer (RAIR-DTC) patients
- Manage adverse events associated with TKIs, including prevention and early detection
- Address the challenges of patient expectations